Moral of the story : Don't stash your hash where somebody can find it kids.




lowrider wrote:Nice to hear a story with a happy ending.





Medicine Man wrote:Not too happy about the impending divorce though but I will get through it.

fent1988 wrote: Once there was a boy, who lived a little city. The boy loved the pleasures of both the Cannabis Sativa and Cannabis Indica plants in the form of their lovely Δ9-tetrahydrocannabinol rich extracts and aromas. He had 6 plants growing in his back yard when one day an evil ogre appeared and smoked up all the young boys hard work. The young boy was terrified and very sad so he built a special cave to keep his special green friends safe. Using hydroponics and experimental lighting he grew himself some new friends. And they pleasured each other in the form of smokey fun and lived happy ever after.

Medicine Man wrote:Drugs on their own are not enough because they do not resolve the cause of the depression. You also have to make a mindset change and really want to deal with your issues.
This patient was given psychological tests both before and after his LSD experience. His score on the Eysenck neuroticism scale before LSD had been in the eighty-eighth percentile-highly neurotic.
One week after LSD his score had swung to the normal portion of the scale. His pre-LSD depression, as measured by the Minnesota Multiphasic Personality Inventory (MMPI), bad lifted and his score was greatly improved.
Tested a third time, six months after LSD, his depression score on the NIMPI was still within normal limits. More important, he had been totally abstinent, and his wife reported that there was a peace and harmony in the home that had never existed before and that he had never been better .
Professor Roland Griffiths, from Johns Hopkins Medical Institutions in Baltimore, Maryland, USA, led the study, the first rigorous investigation of the effects of "tripping" on a drug for decades.
The volunteers were all healthy, well-educated, mostly middle-aged and with no family history of psychotic illness.
Each attended two separate eight hour drug sessions at two month intervals. On one occasion they received psilocybin, on the other the drug Ritalin which was used as a placebo.
Medical professionals were on hand to act as "monitors" and observe what happened. Neither the participants nor the monitors knew when the test drug was being taken.
The trials took place in a room fitted out as a comfortable lounge, with soft music and indirect lighting.
Heart rate and blood pressure were measured, and questionnaires used to assess volunteers' experiences.
During the study, more than 60 per cent of those taking part described the effects of psilocybin in ways that met the recognised criteria of a "full mystical experience".
Two months later, 79 per cent reported moderately or greatly increased well being or levels of life-satisfaction.
Most said their mood, attitudes and behaviour had changed for the better. This was confirmed by interviews with family members, friends and work colleagues.
The findings were published today in the journal Psychopharmacology.
Prof Griffiths said: "Under very defined conditions, with careful preparation, you can safely and fairly reliably occasion what's called a primary mystical experience that may lead to positive changes in a person. It's an early step in what we hope will be a large body of scientific work that will ultimately help people."
This research, amongst others, spurred Griffith to investigate the clinical application of psilocybin for therapeutic purposes. Finding earnest and needing candidates in terminal cancer patients battling depression and anxiety, Griffith established this ongoing trial within the Johns Hopkins Behavioral Pharmacology Research Unit (BFRU). Patients are administered psilocybin via capsule, and brought to a comfortably furnished living room, complete with low lighting, a bohemian decor, headphones for pre-selected music, and a couch. Subjects are encouraged to focus on their “inner experience” during the 8-10 hour duration of the trial. At least one “guide” is at hand throughout the course of the study, and the patients’ blood pressure and heart rate are monitored. Following the completion of two sessions, participants have follow-up interviews in which they discuss their experience and any insight gleamed from it. Additional meetings are scheduled for one month following each session and six months following the final session to review the overall condition of the patient.
Preliminary results are highly encouraging for many volunteers. One subject, a clinical psychologist named Clark Martin, found the depression associated with his kidney cancer debilitating. Despite his expertise in the field, Martin felt completely helpless. Traditional remedies like antidepressant medication and counseling failed to provide meaningful relief. Hearing of Dr. Griffith’s ongoing work, Martin, at age 65, wanted to participate. His experience with the drug was not an uncommon one, “All of a sudden, everything familiar started evaporating. Imagine you fall off a boat out in the open ocean, and you turn around, and the boat is gone. And then the water’s gone. And then you’re gone.” Martin described gaining a newfound sense of empathy, “It was a whole personality shift for me. I wasn’t any longer attached to my performance and trying to control things. I could see that the really good things in life will happen if you just show up and share your natural enthusiasms with people. You have a feeling of attunement with other people.” Over one year later, Martin feels his experience at Johns Hopkins gave him the perspective needed to overcome his depression. Furthermore, he says insights gained during the psilocybin sessions fundamentally changed his relationship with his daughter and friends in a positive, meaningful, and lasting way.Dr. Griffith says that Martin’s experience is fairly typical, and postulates that the capacity for such “unitive” experiences could be hard-wired into the brain, conferring evolutionary advantage through increases in empathy. The trial subjects’ experiences closely reflect accounts of persons undergoing mystical or spiritual transcendence, and it may be that similar associations with religion or meditation occur through neurological conduits also activated by psilocybin.
As to the longterm treatment of depression in cases other than terminal disease, I am skeptical. The efficacy of this remedy decreases with the frequency of its use, physiologically, emotionally, and intellectually. It’s the novelty of the experience that makes it revelatory, and keeping that sense of discovery fresh becomes a tolerance not easily overcome. Life changing insight is not produced by every dose. Psilocybin provides a shock to the intellect, which can broaden perspectives and improve emotional health, but its continuous use will not sustain them.

oldbootzz wrote:what ever happens between two people is meant to be. there is always something waiting for you over the hill. happiness is not a perpetual state. we need the shit times to appreciate the good timesbut one things for sure: you need to have motivation that can get you through. if you dont have it then speak to someone who can give it


Return to General Marijuana Chat
Users browsing this forum: No registered users and 3 guests